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Type 1 diabetes (T1D) is prompted by defective immunological tolerance, an event
in which dendritic cells (DCs) are crucial as immune response orchestrators. In fact,
they contribute to maintaining tolerance to self-antigens, but they can also prompt an
immunogenic response against them, leading to autoimmunity. Countless factors can
potentially impact on the proper functionality of the DCs, which range from altered subset
distribution, impaired phagocytic function to abnormal gene expression. Moreover, in
T1D, metabolic dysregulation could impair DC functions as well. Indeed, since T1D
clinical course is likely to be more aggressive in children and adolescents and entails
severe dysglycemia, the aim of this study was to analyze circulating DCs subpopulations
in pediatric T1D at different stages, as well as to characterize their phagocytosis ability
and tolerance induction potential. Thus, pediatric patients newly diagnosed with T1D,
with established disease and control subjects were recruited. Firstly, DCs subsets
from peripheral blood were found quantitatively altered during the first year of disease,
but recovered in the second year of progression. Secondly, to study the tolerogenic
functionality of DCs, liposomes with phosphatidylserine (PS) were designed to mimic
apoptotic beta cells, which are able to induce tolerance, as previously demonstrated
by our group in DCs from adult patients with T1D. In this study, monocyte-derived
DCs from pediatric patients with T1D and control subjects were assessed in terms of
PS-liposomes capture kinetics, and transcriptional and phenotypic changes. DCs from
pediatric patients with T1D were found to phagocyte PS-liposomes more slowly and less
efficiently than DCs from control subjects, inversely correlating with disease evolution.
Nonetheless, the transcription of PS receptors and immunoregulatory genes, cytokine
profile, and membrane expression of immunological markers in DCs was consistent with
tolerogenic potential after PS-liposomes phagocytosis. In conclusion, T1D progression
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in childhood entails altered peripheral blood DCs subsets, as well as impaired DCs
phagocytosis, although tolerance induction could still function optimally. Therefore, this
study provides useful data for patient follow-up and stratification in immunotherapy
clinical trials.
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INTRODUCTION
Type 1 diabetes (T1D) is prompted by defective immunological
tolerance to beta cells, resulting in their destruction by
autoreactive lymphocytes. Although the triggering factors
causing their activation remain elusive, antigen-presenting cells
(APCs) are known to contribute to this activation, and so,
to the development of the disease. Among APCs, dendritic
cells (DCs), as orchestrators of the immune response, play a
crucial role in the process. On the one side, they can induce
and preserve self-tolerance but, on the other side, they can aid
in its breach. Indeed, many factors could potentially impact
on the proper functionality of the DCs, ranging from altered
subset distribution, impaired phagocytic function, abnormal
gene expression to defective functionality. As a case in point,
many studies have linked the deficient removal of apoptotic beta
cells performed by phagocytes to the initiation of autoimmunity
(1). In fact, beta cells experience massive peaks of apoptosis, not
only as a consequence of the autoimmune attack (2, 3), but also in
physiological islet remodeling during the perinatal period (4, 5).
Plasma membrane integrity is maintained during apoptosis,
thus preventing the release of immunogenic signals (6).
This process, accompanied by fast apoptotic cell clearance
by phagocytes—termed efferocytosis—, allows apoptosis to be
immunomodulatory, which is essential in the maintenance of
homeostasis. Apoptotic cell removal is mediated by highly
conserved receptors and ligands, intracellular signaling, and
engulfment mechanisms. One of the most well-characterized
hallmarks of apoptosis is the exposure of phosphatidylserine
(PS) on the membrane of apoptotic cells (7). PS interacts with
several PS receptors —e.g., MerTK, CD36, and MFG-E8— on
APCs, which promote efferocytosis, and this process confers
biological advantages, such as peripheral self-tolerance induction
(8, 9). Indeed, efferocytosis prompts immunomodulatory effects
in phagocytes, which drive a tolerogenic antigen presentation
and anti-inflammatory mediators production (10). However,
deficiencies in apoptotic cell removal promote the turning
of apoptotic cells into secondary necrotic cells, whereby they
lose their membrane integrity and release danger signals, thus
promoting inflammation and contributing to the initiation of
autoimmunity (11, 12). In fact, accumulating evidence points to
the relevant role of impaired efferocytosis in the development of
multiple sclerosis, rheumatoid arthritis and T1D (13, 14).
Abbreviations: DCs, Dendritic Cells; iDCs, Immature Dendritic Cells; mDCs,
Mature Dendritic Cells; myDCs, Myeloid Dendritic Cells; PBMCs, Peripheral
Blood Mononuclear Cells; PS, Phosphatidylserine; pDCs, Plasmacytoid Dendritic
Cells; TolDCs, Tolerogenic Dendritic Cells.
Interestingly, the gold-standard experimental model of T1D,
the non-obese diabetic (NOD) mouse, harbors a deficiency in
the clearance of apoptotic cells by macrophages (15). In humans,
polymorphisms in the FCGR2A gene, which encodes for the low-
affinity IgG Fc region receptor II-a involved in phagocytosis,
contribute to its pathogenesis (16). However, no data regarding
the phagocytic function of DCs in human T1D are available.
In patients with type 2 diabetes, there is growing evidence that
impaired phagocytosis in neutrophils (17, 18) and macrophages
(19) is related to glycemic control, albeit it can be alleviated with
improved metabolic regulation. These data suggest that changes
in glucose homeostasis can alter phagocytic processes, with the
particularity that impairment of efferocytosis can contribute to
the perpetuation of the autoreactivity in T1D.
By exploiting the inherent ability of apoptotic cell clearance
to induce tolerance, a synthetic lipid-vesicle strategy that
mimics apoptotic beta cells by being enriched in PS and
encapsulating insulin was designed (20). This immunotherapy
arrested autoimmunity upon administration to NOD mice after
PS-liposomes were phagocyted by DCs, thus eliciting tolerogenic
features. This finding was replicated in human DCs from
adult patients with T1D (21). Therefore, this strategy achieves
successful apoptotic mimicry and constitutes a promising
strategy for tackling autoimmune diseases.
Unfortunately, T1D incidence is dramatically increasing in
children (22, 23), in whom the disease is more aggressive
and entails additional management complications. Since severe
dysglycemia could impair DCs functionality, the aim of this study
was to analyze circulating DCs subpopulations in pediatric T1D
at different stages, as well as to characterize phagocytosis in T1D
at the onset—hyperglycemic phase— and at established disease—
when glucose levels are better controlled—, and to evaluate the
role of phagocytosis in tolerance induction.
MATERIALS AND METHODS
Patients and Control Individuals
Pediatric patients with T1D (n = 61) were visited as outpatients
or hospitalized in the Pediatric Section at Germans Trias i Pujol
Hospital. Patients were recruited at the onset and with a longer
evolution (more than 6 months). Pediatric control individuals
(n = 21) were also recruited. Inclusion criteria were 1–18 years
of age and normal body mass index (BMI). Exclusion criteria
were being under immunosuppressive or anti-inflammatory
treatment, the presence of other autoimmune diseases, type 2
diabetes, pregnancy, and compromised kidney or liver function.
All the experiments were carried out in strict accordance with
the principles outlined in the Declaration of Helsinki for human
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research and after the approval of the Committee on the Ethics
of Research of the Germans Trias i Pujol Hospital (PI-16-083).
Signed informed consent was given by the parents of all subjects,
and directly by children older than 12 years old.
Analysis of Peripheral Blood DC Subsets
In order to analyze DCs subsets, 2mL blood samples were
collected in EDTA tubes from control subjects and patients
with T1D at diagnosis, and at first and second year of disease
progression. Blood samples were lysed (Lysing Buffer, BD
Biosciences, San Jose, CA, USA) and stained with antibodies to
CD45-AF700, CD3-APCH7, CD19-APCH7, CD14-V450, CD16-
APC, CD11c-PECy7, CD123-PerCPCy5.5, CD56-PE, HLA-DR-
V500, and Slan-FITC (BD Biosciences). A minimum of 10,000
events per sample was acquired using FACS LSRFortessa
(BD Biosciences). Percentage and absolute counts (cells/µL)
were analyzed using PerfectCount Microspheres (Cytognos SL,
Salamanca, Spain) and FACSDiva software (BD Biosciences)
following gating strategies based on international consensus (24).
Human DC Generation
DCs were generated as described (21). Briefly, peripheral blood
(10mL) was obtained and monocytes were magnetically isolated
using the StraightFrom Whole Blood CD14 MicroBeads kit
(Miltenyi Biotech, Bergisch Gladbach, Germany). Monocytes
were cultured at 106 cells/mL in X-VIVO 15 media (Lonza,
Basel, Switzerland), supplemented with 2% male AB human
serum (Biowest, Nuaillé, France), 100 IU/mL penicillin (Normon
SA, Madrid, Spain), 100µg/mL streptomycin (Laboratorio Reig
Jofré, Sant Joan Despí, Spain), and 1,000 IU/mL IL-4 and
1,000 IU/mL GM-CSF (Prospec, Rehovot, Israel). After 6
days, DCs differentiation yield was assessed by CD11c-APC
staining (Immunotools, Friesoythe, Germany) and viability was
determined by annexin V-PE (Immunotools) and 7-AAD (BD
Biosciences) using FACSCanto II (BD Biosciences).
Preparation of Liposomes
Liposomes consisted of 1,2-dioleoyl-sn-glycero-3-phospho-
L-serine (sodium salt) (Lipoid, Steinhausen, Switzerland),
1,2-didodecanoyl-sn-glycero-3-phosphocholine (Lipoid), and
cholesterol (Sigma-Aldrich). Liposomes were prepared using
the thin-film hydration method from a lipid mixture of
1,2-dioleoyl-sn-glycero-3-phospho-L-serine, 1,2-didodecanoyl-
sn-glycero-3-phosphocholine and cholesterol at 1:1:1.33 molar
ratio, respectively, as described (20). Particle diameter and
surface charge (ζ-potential) were measured by dynamic light
scattering using Malvern Zetasizer (Malvern Instruments,
Malvern, United Kingdom). Fluorescent liposomes (PSOG488-
liposomes) were generated adding lipid-conjugated fluorescent
dye Oregon Green 488 (OG488) 1,2-dihexadecanoyl-sn-glycero-
3-phosphoethanolamine (ThermoFisher Scientific, Waltham,
MA, USA) and had a lipid concentration of 30 mmol/L, a
diameter size of 836 ± 217 nm (mean±SD), and a ζ-potential
of −38.90 ± 2.52mV. PS-liposomes encapsulating human
insulin chains A (PSA-liposomes) and B (PSB-liposomes), were
prepared as described (21) with the following physicochemical
features: PSA-liposomes were 30 mmol/L of lipid concentration,
783 ± 104 nm of diameter and −38.15 ± 1.20mV of ζ-potential;
PSB-liposomes had 30 mmol/L of lipid concentration, 1040 ±
71 nm of diameter and−38.05± 0.07mV of ζ-potential.
Phagocytosis Assay
To determine whether DCs from patients with T1D had a defect
in phagocytosis in the context of apoptotic cell removal, we
tested DCs for their ability to capture synthetic PS-liposomes
that mimic apoptotic beta cells. Then, DCs from control subjects,
recent-onset patients and patients with established disease were
cultured with 100 µmol/L PSOG488-liposomes at 37◦C from
5min to 6 h. As a negative control, the same assay was performed
at 4◦C to confirm that liposomes were captured by phagocytosis.
DCs were extensively washed in cold PBS to remove liposomes
attached to the cell membrane. Liposome capture was assessed
by flow cytometry (FACSCanto II, BD Biosciences).
Gene Expression Analysis
To determine gene expression changes after phagocytosis,
DCs were cultured in basal conditions (immature DCs, iDCs)
and with PS-liposomes encapsulating human insulin chains
A (PSA-liposomes) and B (PSB-liposomes), as described (21).
A mixture of PSA-liposomes and PSB-liposomes (PSAB-
liposomes, 1 mmol/L) were simultaneously cocultured with
DCs from control subjects, recent-onset patients and patients
with established disease at 37◦C for 4 h to promote tolerogenic
features (tolerogenic DCs, tolDCs). RNA was isolated (RNeasy
Micro Kit, QIAGEN, Hilden, Germany) and reverse-transcribed
(High Capacity cDNA Reverse Transcription Kit, ThermoFisher
Scientific). cDNA synthesis reactions were performed using
random hexamers (0.5 mg/mL, BioTools, Valle de Tobalina,
Madrid, Spain) and reverse transcriptase Moloney-murine-
Leukemia-virus (200 U/mL, Promega, Madison, WI, USA).
Targeted cDNA was pre-amplified with TaqMan PreAmp Master
Mix (ThermoFisher Scientific), and qPCR was performed
with TaqMan universal assays (ThermoFisher Scientific)
on a LightCycler R© 480 (Roche, Mannheim, Germany)
using the following ones: CD36 (Hs00354519_m1), CD68
(Hs00154355_m1), CD274 (PD-L1) (Hs00204257_m1),
IDO1 (Hs00984148_m1), IL10 (Hs00961622_m1), LAIR1
(Hs00253790_m1), MERTK (Hs01031979_m1), MFGE8
(Hs00983890_m1), PDCD1LG2 (PD-L2) (Hs00228839_m1),
PPARG (Hs01115513_m1), TGFB1 (Hs00998133_m1), TNFAIP3
(Hs00234713_m1), TNFSF14 (Hs00542476_g1), and VEGFA
(Hs00900055_m1). Relative quantification was performed by
normalizing the expression of each gene to that of the reference
gene GAPDH (Hs02758991_g1), as described in the 2−1Ct
method (25).
DCs Phenotype After Phagocytosis
DCs from patients at onset and with established disease were
cultured for 24 h with 20µg/mL human insulin (Sigma-Aldrich,
St. Louis, MO, USA) and 1 mmol/L of PSAB-liposomes to
determine the effect of insulin chains as autoantigens (tolDCs).
As controls, DCs were either cultured with 20µg/mL human
insulin (Sigma-Aldrich) to obtain iDCs or adding a cytokine
cocktail —TNF-α (1,000 IU/mL, Immunotools), IL-1β (2,000
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IU/mL, Immunotools), and Prostaglandin E2 (PGE2, 1 µmol/L,
Cayman Chemical, Ann Arbor, MI, USA)— for 24 h to obtain
mature DCs (mDCs). Viability and phenotype were analyzed
by flow cytometry (FACSCanto II, BD Biosciences). DCs were
stained with 7-AAD (BD Biosciences) and antibodies to CD11c-
APC, CD86-FITC, HLA-ABC-FITC, HLA-DR-FITC, CD14-
PE and CD40-APC (Immunotools), CD36-APCCy7, TIM4-
APC, αvβ5 integrin-PE, CD54-PECy7, TLR2-FITC, CXCR4-
APCCy7, CCR2-APC (BioLegend, San Diego, CA, USA). Data
were analyzed using FlowJo software (Tree Star Inc, Ashland,
OR, USA).
Cytokine Production
The Human Th1/Th2/Th17 kit (CBA system; BD Biosciences)
was used to measure cytokine production. Culture supernatants
from DCs (n≥3 for control subjects and n≥3 for patients
with T1D) were collected and frozen at −80◦C until use. IL-
2, IL-4, IL-6, IFN-γ, TNF-α, IL-17A, and IL-10 were assessed.
Data were analyzed using CBA software. VEGFA secretion
by DCs was determined in culture supernatant by ELISA
(ThermoFisher Scientific).
Statistical Analysis
Prism 7.0 software (GraphPad Software Inc, San Diego, CA,
USA) was used for the statistical analysis. For comparisons of
unpaired data, a non-parametric Mann-Whitney test was used;
for paired comparisons, the non-parametric Wilcoxon test was
used. ANOVAwas used for comparisons with several factors. For
correlation between parameters, Spearman’s test was used. A p
value< 0.05 was considered significant.
RESULTS
DCs Subsets From Peripheral Blood Are
Altered at the Onset and Early Stages of
T1D Progression
As a first approach, different subsets of circulating DCs were
assessed in control subjects and patients with T1D at diagnosis,
and at first year and second year of progression. Their clinical
data are summarized in Table 1. All subjects met the inclusion
and exclusion criteria and gave informed consent. Aside from
differences in the evolution of the disease, patients at onset
showed higher glycated hemoglobin (HbA1c) levels than patients
at first year and at second year of progression. Patients at second
year of progression required higher insulin doses than patients at
onset and at first year of evolution.
Thus, four different subsets of DCs in peripheral blood [total
DCs, myeloid DCs (myDCs), plasmacytoid DCs (pDCs) and a
CD11c−CD123− putative DC subset] were analyzed (Figure 1)
following the gating strategy displayed in Figure S1. As for total
DCs, percentages and numbers were decreased in patients at first
year when compared to control subjects, although patients at
second year recovered a normal percentage. The percentage of
myDCs was increased in patients at first year when compared
to control subjects, patients at onset and at second year of
progression, although no differences were observed in their
numbers. As for pDCs, patients at first year displayed a higher
TABLE 1 | Data from the patients with T1D and control subjects included in the
peripheral blood DCs subsets analysis.
Parameter Control
subjects
Patients at
onset
Patients at
first year
of evolution
Patients at
second year
of evolution
n 10 11 11 6
Gender F/M 6/4 (60%/40%) 6/5 (55%/45%) 8/3 (73%/27%) 5/1 (83%/17%)
Age (years) 7.36 ± 2.52 8.35 ± 5.92 10.73 ± 3.73 10.02 ± 2.78
BMI (kg/m2) 17.42 ± 2.19 17.19 ± 3.05 17.94 ± 2.59 18.13 ± 2.23
Age at
diagnosis
(years)
NA 8.35 ± 5.92 10.17 ± 3.70 8.45 ± 2.73
Progression
(years)
NA 0.00 ± 0.00 0.56 ± 0.18**** 1.57 ±
0.10****/++++
HbA1c
(mmol/mol)
NP 92.05 ± 22.36 55.79 ±
10.78****
67.21 ± 12.76*
HbA1c (%) NP 10.57 ± 2.05 7.25 ± 0.99**** 8.30 ± 1.17*
Fasting
C-peptide
(ng/mL)
NP 0.40 ± 0.40 <0.1 in 6/11
(55%) patients
0.72 ± 0.90
<0.1 in 3/6
(50%) patients
0.27 ± 0.06
Stimulated
C-peptide
(ng/mL)
NP 0.98 ± 1.02 NP NP
Insulin dose
(IU/kg/day)
NA 0.70 ± 0.19 0.60 ± 0.24 0.96 ± 0.18*/++
Data presented as mean ± SD; p value calculated from Mann-Whitney test (*p < 0.05,
****p< 0.0001 when comparing pediatric patients at onset group with pediatric patients at
first or second year of evolution; ++p< 0.01, ++++p< 0.0001 when comparing pediatric
patients at first year of evolution with those at second year of evolution).
F, female; M, male; BMI, Body Mass Index; NA, Not Applicable; HbA1c, glycated
hemoglobin; NP, Not Performed.
percentage than patients at onset and patients at second year. The
numbers of pDCs were higher in control subjects when compared
to patients at onset and at first year. Finally, patients at first year
had a decreased percentage of the CD11c−CD123− subset when
compared to control subjects, patients at onset and at second year,
and their numbers were also lower when compared to control
subjects and patients at second year. Therefore, DCs subsets from
peripheral blood were found quantitatively altered during the
first year of childhood T1D and recovered in the second year
of progression.
DC Differentiation Efficiency Is Similar in
Pediatric Patients and Control Subjects
After observing alterations in DCs subsets in pediatric patients
with T1D, and in order to assess their functionality, DCs
were derived from peripheral blood monocytes from patients at
diagnosis and with established disease as well as from control
subjects. Their clinical data are summarized in Table 2. The
BMI of patients with established disease was significantly higher
than that of control subjects and patients at onset. As expected,
patients with established disease had a longer evolution and
significantly lower HbA1c values than patients at onset. Then,
monocytes were magnetically isolated directly from whole blood,
and differentiated into DCs in vitro. The number of isolated
CD14+ cells (monocytes), viability, and dynamics of the CD11c
marker acquisition (differentiation to DCs) at days 1, 4, and 6 of
culture showed similar values in the three groups (Table 3).
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FIGURE 1 | Peripheral blood DC subsets are quantitatively altered at the early stages of T1D. Percentages (left panel) and concentration (cells/µL, right panel) of total
DCs (1st row, HLA-DR+ cells of CD3−CD19−CD56−CD14− cells), myeloid DCs (myDCs, 2nd row, CD11c+CD123− cells of HLA-DR+ cells), plasmacytoid DCs
(pDCs, 3rd row, CD11c−CD123+ of HLA-DR+ cells) and the CD11c−CD123− subset (4th row, CD11c−CD123− of HLA-DR+ cells). Data are expressed as mean ±
SD; white squares are control subjects (n = 10), white circles are patients at onset (n = 11), black dots are patients at first year of progression (n = 11), and black
rhombuses are patients at second year of progression (n = 6). Statistically significant differences were found when comparing the groups (*p < 0.05, **p < 0.01,
Mann-Whitney test).
DCs From Patients With T1D Display
Impaired Phagocytic Activity in Correlation
With Disease Progression
In order to test the ability of DCs to phagocyte lipid vesicles in
the context of apoptotic cell removal, fluorescent PS-liposomes
were used in a time-course experiment, coculturing PSOG488-
liposomes with DCs from each group of subjects. As expected,
phagocytosis was not observed at 4◦C (Figure 2A). At 37◦C
(Figures 2A,B), the phagocytosis rate of PSOG488-liposomes
by DCs from patients with established disease was decreased
when compared to control subjects, starting at 15min of
coculture and throughout the assay. Moreover, DCs from
patients with established disease had phagocyted lower levels of
PSOG488-liposomes than patients at onset at 2 h of coculture.
No significant differences were found when comparing the
phagocytosis kinetics of DCs from patients at onset and control
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TABLE 2 | Main clinical characteristics and metabolic data of participants
included in the study of phagocytosis and tolerance induction.
Parameter Control
subjects
Patients
at onset
Patients with
established disease
n 11 14 19
Gender F/M 8/3 (73%/27%) 9/5 (64%/36%) 12/7 (63%/37%)
Age (years) 9.56 ± 1.66 9.74 ± 3.54 12.13 ± 3.92
BMI (kg/m2 ) 17.50 ± 2.61 16.57 ± 3.08 20.33 ± 3.80*/++
Age at diagnosis
(years)
NA 9.74 ± 3.54 8.46 ± 3.28
Progression (years) NA 0.00 ± 0.00 3.66 ± 3.00++++
(range: 0.5–11.7 years)
HbA1c (mmol/mol) NP 113.50 ± 20.92 61.92 ± 8.75
++++
HbA1c (%) NP 12.54 ± 1.92 7.82 ± 0.80
++++
Fasting C-peptide
(ng/mL)
NP 0.46 ± 0.28 <0.1 in 13/19 patients
(68%)
0.4 ± 0.32
Stimulated
C-peptide (ng/mL)
NP 0.88 ± 0.58 NP
Insulin dose
(IU/kg/day)
NA 0.85 ± 0.22 0.89 ± 0.17
Data presented as mean ± SD.
p value calculated from Mann-Whitney test (*p < 0.05 when comparing either group of
patients to the control group; ++p < 0.01, ++++p < 0.0001 when comparing patients at
onset with those with established disease).
F, female; M, male; BMI, Body Mass Index; NA, Not Applicable; HbA1c, glycated
hemoglobin; NP, Not Performed.
TABLE 3 | Data from monocyte isolation and DC differentiation.
Parameter Control
subjects
Patients at
onset
Patients with
established disease
n 11 14 19
Isolated CD14+ cells
(day 1, ×106 cells)
2.60 ± 0.84 2.83 ± 1.46 2.57 ± 1.07
Viability (day 1, %) 96.13 ± 2.34 96.29 ± 3.33 97.16 ± 1.87
CD11c purity
(day 1, %)
4.23 ± 3.24 4.56 ± 2.68 5.41 ± 4.87
Differentiation
efficiency (CD11c
purity, day 4, %)
63.50 ± 18.59 61.46 ± 25.27 71.74 ± 25.79
Differentiation
efficiency (CD11c
purity, day 6, %)
92.17 ± 6.06 88.31 ± 9.19 86.95 ± 13.08
Data presented as mean ± SD. No statistical differences were found between groups
(Mann-Whitney test).
subjects. To further dissect this finding, the area under the curve
(AUC) of the kinetics of capture was calculated (Figure 2C). The
AUC values of patients with established disease were significantly
lower than those of patients at onset and control subjects.
Also, patients at onset had significantly lower AUC values than
control subjects. Therefore, the correlation between AUC values
and the time of disease progression was analyzed (Figure 2D),
discovering that both parameters were significantly and inversely
correlated (Spearman’s r = −0.664, p = 0.022). This defect
was only observed in children with T1D, and not in adults, as
previously reported (21). Thus, and as an additional control, we
have included in this study a phagocytosis assay with DCs from
adult patients with established disease, which demonstrates that
the impairment of phagocytosis is an inherent feature of pediatric
T1D (Figure S2 and Table S1).
Efferocytosis and
Immunoregulation-Related Gene
Expression Is Altered in DCs From Patients
With T1D
Since the phagocytic capacity of DCs from patients with T1D was
altered, the gene expression of specific PS receptors (CD36,CD68,
MERTK, MFGE8), and immunoregulatory molecules (PPARG,
TNFAIP3, TNFSF14, LAIR1, PDL1, PDL2, TFGB1, and VEGFA)
was evaluated in DCs before (iDCs) and 4 h after (tolDCs)
coculture with PSAB-liposomes in the three groups: control
subjects, patients at onset and patients with established disease
(Figure 3). All these genes were expressed in iDCs. Firstly, no
significant differences in the expression of CD36, CD68 nor
MERTK were found between groups, but a significant reduction
in MFGE8 expression was detected in DCs from patients with
established disease in comparison to the other groups. Moreover,
after liposome capture, the expression levels of genes of PS
receptors were preserved or even showed a tendency to increase
in comparison to iDCs. In this sense, a tendency for upregulation
of MERTK —a feature of tolDCs (26)— was observed in tolDCs
from control subjects (p= 0.06).
Regarding genes of immunoregulatory molecules, PPARG and
LAIR1 expression discerned both stages of T1D, being higher in
established disease than at the onset and controls. Patients with
T1D also showed higher levels of TNFAIP3, TNFSF14, PDL1,
PDL2, and TGFB1 in DCs than controls. Interestingly, tolDCs
from patients exhibited a trend for upregulation of the TNFAIP3,
TNFSF14, and TGFB1 genes upon PSAB-liposomes capture at
different stages of the disease. Finally, VEGFA gene expression
did not differ between groups nor after the capture of PSAB-
liposomes. Concerning IDO1 and IL10, a low expression was
detected in all conditions (Figure S3).
DCs From Pediatric Patients Acquire a
Tolerogenic Potential After Phagocytosis
of PS-liposomes
In terms of cytokine secretion by DCs, the release of IL-6, TNF-
α, IL-10, and VEGFA by DCs from control subjects, recent-onset
patients and patients with established disease was consistent
with a tolerogenic profile after PSAB-liposomes phagocytosis
(Figure 4). Briefly, IL-6 concentration was similar before (iDCs)
and after (tolDCs) PSAB-liposomes uptake in all groups.
Moreover, IL-6 secretion increased after maturation stimulus in
DCs (mDCs) from patients with established T1D, and the same
trend was observed in the other groups. Similarly, TNF-α was
not increased after liposome uptake, and its secretion tended
to increase in pro-inflammatory conditions. IL-10 concentration
was detected around the limit of detection in all samples.
Remarkably, VEGFA concentration was slightly increased in the
supernatant of DCs after liposome uptake when compared to that
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FIGURE 2 | DCs from patients with T1D show impaired phagocytic activity in correlation with the time of disease progression. (A) Flow cytometry contour plots and
percentages of the capture of PSOG488-liposomes by DCs (CD11c+). From left to right, control DCs cultured with PSOG488-liposomes at 4◦C for 1 h, and DCs from
control subjects, patients at onset and patients with established disease cultured with PSOG488-liposomes at 37◦C for 1 h. One representative experiment of 6 is
shown. (B) Time-course of the capture of PSOG488-liposomes by DCs obtained from control subjects (white squares, n = 6), pediatric patients at onset (white
circles, n = 6) and with established disease (black dots, n = 6) at 37◦C. Results are mean±SEM. Comparisons between groups showed significant differences (*p <
0.05, ***p < 0.001, ****p < 0.0001 when comparing control subjects with patients with established disease; ++p < 0.01 when comparing patients at onset with
patients with established disease, Two-way ANOVA). (C) Area under the curve (AUC) of phagocytosis kinetics curves. Differences were found between groups (*p <
0.05, **p < 0.01, Mann-Whitney test). (D) Correlation between AUC values of phagocytosis kinetics curves and disease progression. A significant correlation was
found between both parameters (Spearman’s r = −0.664, p = 0.022, Spearman’s correlation analysis).
of iDCs in control subjects and patients with established disease
—although patients at onset showed the same tendency (p =
0.06). IL-2, IL-17A, and IFN-γwere not detected in any condition
of the assay (data below the detection limit). These results,
although not always statistically significant, support the ability of
DCs from children with T1D to achieve a tolerogenic phenotype.
Afterward, we interrogated whether the phenotype of DCs
from patients changed toward a tolerogenic profile after
24 h of coculture with PSAB-liposomes (tolDCs), despite the
phagocytosis defect. First, the viability of DCs from all groups
was higher than 90% in all conditions, thus confirming that PS-
liposomes are not toxic to DCs obtained from pediatric subjects
(data not shown). No differences were observed in the DCs
phenotype between patients at onset or with established disease,
under any of the conditions (Figure 5). Membrane expression of
PS receptors such as CD36, TIM4 and Integrin αvβ5 was not
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FIGURE 3 | The expression of genes related to efferocytosis and immunoregulation is altered in DCs from patients with T1D. Expression of CD36, CD68, MERTK,
MFGE8, PPARG, LAIR1, TNFAIP3, TNFSF14, PDL1, PDL2, TGFB1, and VEGFA genes in immature DCs (iDCs) before and 4 h after (tolDCs) coculture with
PSAB-liposomes, analyzed by qPCR. White squares are control subjects (n = 5), white circles are patients at onset (n = 3-5), and black dots are patients with
established disease (n = 6). Bars show the mean ± SD. Gene expression signals were normalized to GAPDH expression. No significant differences were found when
comparing culture conditions in the same group (Wilcoxon test). Significant differences were found when comparing the same culture conditions in the three groups
(+p < 0.05, ++p < 0.01, Mann-Whitney test).
altered after liposome capture in comparison to iDCs. Then,
the expression of molecules related to the immune function
of DCs was assessed. Antigen-presenting molecules HLA-ABC
displayed a trend for lower expression in tolDCs when compared
to mDCs in patients with established disease (p = 0.08); HLA-
DR expression did not exhibit any changes. As for adhesion
molecules such as CD54, in patients with established disease,
tolDCs showed a tendency for higher expression than iDCs (p =
0.06). Regarding costimulatorymolecules CD40 and CD86, lower
expression was observed in tolDCs when compared to mDCs in
patients with established disease, and patients at onset displayed
the same pattern. Chemokine receptors CXCR4 and CCR2
were not upregulated after phagocytosis; however, mDCs from
patients with established disease tended to express higher levels
of these molecules when compared to iDCs and tolDCs (p =
0.06). Finally, no defects in the expression of pattern recognition
receptors, TLR2 and CD14, were observed in DCs under
any conditions.
DISCUSSION
It is well-known that DCs, as orchestrators of the immune
response with a crucial role in maintaining self-tolerance, are
highly involved in the pathogenesis of T1D. Several studies
have enumerated the broad spectrum of alterations that DCs
from these patients have, ranging from genetic alterations,
to phenotypic and functional divergences (16). Fewer studies,
however, have focused on the potential of DCs from adult
patients to become tolerogenic (27, 28), but no data are available
in pediatric patients. To our knowledge, this is the first work
that assesses DCs subsets in children with T1D at different
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FIGURE 4 | The cytokine profile after the uptake of PSAB-liposomes by DCs points to tolerogenic potential. Concentration of IL-6, TNF-α, IL-10, and VEGFA secreted
by DCs obtained from control subjects (white squares, n ≥ 3), patients with T1D at onset (white circles, n ≥ 3) and patients with established disease (black dots, n ≥
3). Bars represent immature DCs (iDCs), immature DCs 4 h after the capture of PSA-liposomes and PSB-liposomes (tolDCs), or mature DCs (mDCs) induced with a
cytokine cocktail. Data presented as mean ± SD. Significant differences were found when comparing the different conditions in the same group of subjects (*p <
0.05, Wilcoxon test). Differences were not found when comparing the same culture condition in the three groups (Mann-Whitney test).
stages of the disease and evaluates their tolerogenic potential.
Indeed, we believe these are paramount aspects to consider
in the near future, when antigen-specific immunotherapies
will be available and immunomonitoring of the patients will
be required.
Thus, peripheral blood DC subsets were measured to
determine quantitative alterations related to disease progression.
Interestingly, most of the differences gathered in the first year of
evolution were restored in the second year. Briefly, the percentage
of myDCs and pDCs was increased at diagnosis when compared
to the other time points, whereas the CD11c−CD123− subset
was decreased. In this sense, alterations in myDCs and pDCs
subsets have been reported in children with T1D at initial
stages of disease (29–31), and further efforts are warranted
to validate the usefulness of DC subsets as biomarkers in the
progression of the disease and to provide further insight into their
biological significance.
The alteration in DCs subsets at the early stages of T1D
was an early observation that prompted us to study the
tolerogenic functionality of DCs. To do so, we employed a
nanotherapy imitating apoptotic beta cells consisting of PS-
liposomes encapsulating insulin (20). These liposomes were
phagocyted by murine DCs, thus arresting autoimmunity in the
experimental model of the disease, and also induced tolerogenic
features in human DCs from adult patients with T1D (21).
In the present study, three similar groups of pediatric
subjects in terms of gender and age were included. Patients
with established disease had higher BMI, which was expected
according to the recovery of weight after disease onset and to
the distribution of BMI related to age (32), but nonetheless
healthy, in order to avoid the hypothetical interference of
inflammatory processes associated with overweight and obesity.
Quite unexpectedly, here we found that the phagocytic activity
of monocyte-derived DCs from pediatric patients with T1D was
impaired, and this defect deteriorated with the progression of
the disease but did not affect the induction of a tolerogenic
phenotype after phagocytosis. This immune dysfunction, not
previously reported in pediatric patients with T1D, agrees with
studies that have reported an impaired phagocytic activity in
macrophages from the NOD mouse, both at early ages—before
diabetes development—and at adulthood when compared to
other strains (15). An attenuated phagocytic activity has also been
found in patients with type 2 diabetes, but it was reversed after
the improvement of glycemic control (19). Moreover, a reduced
capacity for efferocytosis has been reported in other autoimmune
diseases unrelated to glucose metabolism (13). In addition,
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FIGURE 5 | Phagocytosis of PS-liposomes induces a tolerogenic phenotype in DCs from pediatric patients both at onset and established T1D. Membrane expression
of CD36, TIM4, Integrin αvβ5, HLA-ABC, HLA-DR, CD54, CD40, CD86, CXCR4, CCR2, TLR2, and CD14 molecules in DCs obtained from patients at onset (white
circles, n = 2–3) and with established disease (black dots, n = 4–9). Bars represent immature DCs (iDCs), iDCs after the capture of PSAB-liposomes (tolDCs), and
mature DCs (mDCs) induced with a cytokine cocktail, after 24 h. Data are mean ± SD of relative Median of Fluorescence Intensity (MFI), this being MFI of each
condition referred to their respective mDCs control. Significant differences were found when comparing culture conditions in the same group (*p < 0.05, **p < 0.01,
Wilcoxon test), but not when comparing the same culture conditions in both groups (Mann-Whitney test).
Frontiers in Immunology | www.frontiersin.org 10 November 2019 | Volume 10 | Article 2811
Rodriguez-Fernandez et al. Dendritic Cells in Pediatric T1D
specific PS receptors are crucial in efferocytosis. As expected,
mice deficient in PS receptors show impaired efferocytosis
and increased inflammation (11). Overall, these data suggest
that several factors, e.g., intrinsic defects, dysglycemia and
inflammation, may contribute to the impairment of phagocytosis
in T1D. It is well-known that efferocytosis is not only a
mechanism of apoptotic cell removal but also a crucial process
in the maintenance of immunological homeostasis, and so this
defect could contribute to the persistent lack of self-tolerance.
Although DCs from pediatric patients with T1D were
found to have impaired phagocytosis in correlation with
disease progression, DCs from patients at onset and with
established disease showed similar expression of PS receptors
(CD36, CD68, and MERTK), except for MFGE8. Interestingly,
DCs from patients with established disease had a decreased
MFGE8 expression, and this defect could contribute to the
herein reported phagocytosis impairment. Since several PS
receptors work to internalize apoptotic cells (33), the suboptimal
expression or function of any of them could explain the altered
phagocytosis. In fact, scarce information has been reported about
DCs phagocytic activity, since most studies have been conducted
with macrophages. Thus, it is plausible that DCs may express the
same PS receptors as macrophages but in different proportions,
or express entirely different PS receptors (34), which could be
accountable for the impaired phagocytosis of DCs.
As for the immunoregulatory profile, DCs from pediatric
patients with T1D showed higher expression of PPARG and
TGFB1—two genes downstream in the efferocytosis signaling
pathway—than control subjects. Moreover, TNFAIP3 displayed
higher expression in DCs from patients; interestingly, the
expression of Tnfaip3 in murine DCs was reportedly upregulated
after efferocytosis (35), thus reducing their rate of apoptotic
cell clearance and prompting their acquisition of tolerogenic
potential (36). Also, the overexpression of LAIR1—detected in
DCs from patients with established disease—has been linked
to an inhibition of cholesterol-particle phagocytosis by murine
macrophages (37). Thus, the expression of these two genes
combined could also provide a plausible explanation for the
observed impaired phagocytosis of PS-liposomes. In addition,
their higher expression in comparison to control subjects, along
with that of PPARG, PDL1, PDL2, and TGFB1 genes, could reflect
a continuous attempt of immunoregulation prompted by the
ongoing autoimmune reaction (38). Importantly, the expression
of tolerogenic markers was also found upregulated in adult DCs
after the capture of PSAB-liposomes in our previous RNA-seq
analysis (21). However, other factors, such as IDO and IL-10, have
been shown to inhibit T cell activation by DCs after efferocytosis,
but we did not observe any increase in IDO1 and IL10 expression,
in line with similar studies (39).
Moreover, the results of the characterization of the cytokine
profile in DCs from pediatric patients were similar to those
reported in adults (21), and support the ability of DCs from
children with T1D to achieve a tolerogenic phenotype. As in
adults, IL-10 was detected at very low levels in all conditions,
correlating with the above-mentioned gene expression results,
although this could be explained by the timing of the
experiment. Nevertheless, it is worth mentioning the profile
of VEGFA secretion—a cytokine involved in the inhibition of
DCs maturation after apoptotic cell removal (40, 41)—, in
which tolDCs from the three groups released higher levels of
VEGFA in comparison to iDCs, 4 h after phagocytosis. This
further supports that DCs acquire tolerogenic properties after
PS-liposomes phagocytosis, even if their phagocytosis ability is
impaired. Overall, these results suggest that DCs from patients
could mediate immunoregulatory attempts.
Finally, membrane expression of PS receptors and immune-
related molecules in DCs from pediatric patients with T1D was
also studied to determine whether the activation of tolerogenic
signaling pathways was translated to the DC membrane. These
PS receptors are expressed in iDCs to allow apoptotic cell
phagocytosis. As described previously (21), the expression of PS
receptors was maintained after PSAB-liposomes phagocytosis or
even showed a tendency to increase in comparison to iDCs,
thus preserving the ability to efferocyte. As for the expression
of immune-related molecules, tolDCs from pediatric patients,
both at onset and with established disease, showed a pattern
consistent with tolerogenic potential. Indeed, this phenotype
is similar to that displayed by DCs after PS-liposomes uptake
in murine models of T1D and multiple sclerosis (20, 42),
and also in human DCs from adult patients with T1D (21).
However, the main limitation in the studies of tolDCs is the
lack of a robust single marker of tolerogenic potential, and
so several parameters that altogether point to the tolerogenic
potential of DCs are usually determined. To date, tolDCs are
accepted as reluctant to maturation and stable in a state of low
expression of antigen-presenting and costimulatory molecules,
along with a tolerogenic-skewed cytokine profile (43). Thus, the
here presented data are consistent with a biological tolerogenic
effect in pediatric DCs after liposome uptake.
We are well-aware of the limitations of the study. On the
one hand, efferocytosis of apoptotic beta cells was mimicked
using previously-described synthetic microvesicles displaying
features of apoptotic cells (20). However, the engulfment of
these liposomes by DCs induces similar effects to those observed
by physiological apoptotic cell phagocytosis and constitutes a
good system to test the fitness of DCs. On the other hand,
only six PS receptors were explored, and despite their crucial
role in efferocytosis, other receptors could be altered in T1D
thus impairing DCs phagocytosis. Whether this alteration is
instrumental in the progression of the autoimmune attack toward
the clinical manifestation of T1D is currently under investigation.
In fact, when the clinical diagnosis of T1D takes place, there
is already a significant loss of beta cells in the pancreas of the
patient. However, in this scenario, autoimmunity to beta cells
remains active despite the low numbers of alive or functional beta
cells in the pancreatic islets, and it can destroy these remaining
beta cells. Thus, the altered phagocytic activity observed in
DCs could be translated into impaired phagocytosis of actual
apoptotic beta cells, which could facilitate their conversion into
secondary-necrotic cells if they are not efficiently removed by
phagocytes. This happening would increase the availability of
danger signals and feed the autoimmune process against beta
cells. Perhaps, children susceptible to the disease may carry a
defect in the efferocytosis ability of phagocytes, which could
further exacerbate immunogenic responses. Interestingly, the
here identified defect in the phagocytic activity of DCs from
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pediatric patients with T1D was not detected in adult patients
(21), so we can speculate that childhood features (growth,
puberty, environmental factors) and diabetes (metabolic control,
immune response heterogeneity) could influence DCs behavior
(44, 45). Nevertheless, the preservation of the tolerogenic
potential in DCs from pediatric patients with T1D could help
in restraining the autoimmune destruction of beta cells, and in
preserving the residual beta cell mass in patients with T1D.
In conclusion, pediatric peripheral DCs subsets are altered in
the first stages of T1D and their phagocytic capacity deteriorates
with disease progression, although tolerance induction could still
function optimally. Despite further studies to draw the intricate
picture of this phagocytosis impairment are needed, both the
study of peripheral blood DCs and functional DCs studies
provide useful data in patient’s follow up, and could aid in the
stratification of patients in immunotherapy clinical trials, since
these results could inform about the immunological status of the
patients’ DCs and their ability to promote a tolerogenic response.
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